ClinicalTrials.gg
Active, not recruitingNCT04017455TARZANUpdated Sep 30, 2026

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

A Phase 2 interventional study of Atezolizumab and Bevacizumab in Rectal Cancer, sponsored by The Netherlands Cancer Institute. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by The Netherlands Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Updated Sep 30, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies testing bevacizumab in Rectal Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. Bevacizumab · Rectal Neoplasms.

Planned enrollment
46th of 80
38 · median 45
Started
2019
with 3 others
Phase 2
51 of 83
4 open now
Primary completion
2028-12
later than 8 of 10 live
Registered
69th of 83
by date

Among the 83 studies testing bevacizumab in Rectal Neoplasms, this one is the 46th largest by planned enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2019, is one of 51 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 69th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

8 of the 83 studies testing bevacizumab in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing bevacizumab in Rectal Neoplasms, or all of them as a file.
02

Study summary

In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab

Read the detailed description

38 patients with resectable rectal cancer will be enrolled. All patients will be treated with radiotherapy followed by bevacizumab and atezolizumab.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • short term immunotherapy
  • atezolizumab
  • bevacizumab
  • radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed
  • patients age 18 years and older
  • confirmed adenocarcinoma of the rectum
  • intermediate risk rectal cancer or low risk distal rectal cancer

Exclusion criteria

Exclusion Criteria:

  • evidence of disease
  • prior radiation therapy for disease under study
  • prior treatment with CD137 agonists or immune checkpoint blockade therapies
  • current or recent use of acetylsalicylic acid
  • history of cardiac or pulmonary dysfunction pregnancy or breastfeeding
  • significant auto-immune disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    bevacizumab and atezolizumab

    1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy

    Drug: Atezolizumab · Drug: Bevacizumab

Interventions

  • 3 cycles of atezolizumab 840 mg

    Also known as: MPDL3280A

  • 3 cycles of bevacizumab 5mg/kg

    Also known as: HCA 185 ,Avastin

06

What researchers measure

Primary outcomes

  1. clinical complete and near-complete response rate

    response rate will be assessed by MRI and endoscopy

    Time frame: 12 weeks post-radiotherapy

Secondary outcomes

  1. incidence of adverse events following treatment (safety)

    adverse events will be assessed (according tot CTC-AE v5) during treatment

    Time frame: untill 100 days after last patient last study drug

  2. local recurrence rate at 1 year follow-up

    recurrence will be assessed by MRI and CT scans

    Time frame: 1 year post-radiotherapy

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Dec 2028, 110 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 110 months is above that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Aug 2025 → Dec 2028 and completion Aug 2025 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 12, 2019
StartActual
Oct 22, 2019
Primary completionEst.
Dec 31, 2028was Aug 2025
CompletionEst.
Dec 31, 2028was Aug 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Marieke van de Belt · Amsterdam, Netherlands
Show 1 removed
  • Marieke van de Belt · Amsterdam, Netherlands
Sep 30, 2026
Primary completion
Aug 31, 2025→Dec 31, 2028
Sep 30, 2026
Study completion
Aug 31, 2025→Dec 31, 2028
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site added, 1 site removed
    Show site
    • Marieke van de Belt · Amsterdam, Netherlands
    Show 1 removed
    • Marieke van de Belt · Amsterdam, Netherlands
    Primary completion Aug 31, 2025→Dec 31, 2028
    Study completion Aug 31, 2025→Dec 31, 2028
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04017455
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 12, 2019
Start date
Oct 22, 2019
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Myriam Chalabi, MD
principal investigator · Antoni van Leeuwenhoek

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion